CCL5 and prostate cancer: Using a coculture of C4-2 cells, a metastatic prostate cancer cell line, and human umbilical vein endothelial cells (HU-VEC), the authors show that HUVEC enhanced prostate cancer cell invasion by decreasing androgen receptor (AR) activity in a C-C chemokine ligand type 5 (CCL5)- dependent manner.